Swiss drug maker Novartis AG has reported that an MS patient treated with oral MS pill Gilenya has been diagnosed with a rare but highly fatal brain disease. According to the Swiss drug maker, the patient developed progressive multifocal leukoencephalopathy or PML, which is a rare but fatal form of brain disease. But in addition,